Analyst Josh Jennings of TD Cowen maintained a Buy rating on Boston Scientific, retaining the price target of $100.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Josh Jennings has given his Buy rating due to a combination of factors, starting with his view that the recent share price weakness does not reflect Boston Scientific’s underlying fundamentals or outlook. Management reiterated strong confidence in achieving both near-term goals and its 2026 plan, underpinned by double‑digit organic revenue growth and a pipeline that supports its long‑range targets through 2028.
He also highlights that Boston Scientific is driving operating margin expansion and double‑digit EPS growth, helped by a richer mix of higher‑margin products such as key electrophysiology offerings and Watchman. While some headwinds from supply chain spending and tariffs may keep gross margins roughly stable, the company’s scale efficiencies, portfolio strength, and limited direct exposure to geopolitical disruptions support the view that execution on guidance can restore investor confidence and re‑rate the stock higher.
In another report released yesterday, Bank of America Securities also reiterated a Buy rating on the stock with a $105.00 price target.